FDA Submission Update for ONTRUZANT (BLA761100) by Samsung Bioepis
The FDA has received a supplemental application (BLA761100) for ONTRUZANT, an HER2-targeting biosimilar.
Asset
ONTRUZANT
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's receipt of a supplemental application for ONTRUZANT signals an important development in the competitive landscape of HER2-targeting biosimilars. This could affect pricing strategies and market dynamics for existing trastuzumab products, necessitating close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approval announcements.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.